Literature DB >> 21644322

[Study on the efficacy graded-disease-spectrum of acupuncture and moxibustion by the fuzzy comprehensive evaluation techniques: musculoskeletal and connective tissue diseases].

Yuan-Hao Du1, Jun Xiong, Bo Li, Yan-Long Xu, Wei-Hong Liu, Ying Li, Jing Li, Lei Shi, Xiao-Miao Lin, Li Xiao.   

Abstract

The descriptive cross sectional surveys were carried out among the outstanding clinical physicians in the field of acupuncture and moxibustion by using the survey sampling. The fuzzy comprehensive evaluation techniques was applied to evaluate the opinions of clinical experts in the field of acupuncture and moxibustion in order to classify the spectrum of diseases related to the musculoskeletal and connective tissue. After the statistical analysis on sixty-four diseases with 104 subtypes, the spectrum of diseases were determined as grade I spectrum of diseases with 13 subtypes of diseases, grade II spectrum of diseases with 51 subtypes of diseases, grade III spectrum of diseases with 10 subtypes of diseases, and grade IV spectrum of diseases with 30 subtypes of diseases. The outcomes reveal that acupuncture and moxibustion therapy have been applied widely for musculoskeletal diseases and connective tissue related diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21644322

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  2 in total

1.  Clinical efficacy evaluation of a traditional Miao technique of crossbow needle therapy in the treatment of knee osteoarthritis: a multi-center randomized controlled trial.

Authors:  Jing Fu; Hong-Cai Shang; Li-Ying Wang; Chen Zhao; Xiao-Fang Yang; Wei-Wei Guo; Chun-Xia Lu; Jin Cui; Yan-Ping Wang
Journal:  Trials       Date:  2020-06-22       Impact factor: 2.279

2.  Crossbow needle therapy of the Miao ethnic minority group for knee osteoarthritis: study protocol for a randomized controlled trial.

Authors:  Jing Fu; Hong-Cai Shang; Li-Ying Wang; Chen Zhao; Jin Cui; Yan-Ping Wang
Journal:  Trials       Date:  2018-06-27       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.